Introduction
Discovery of DFS70/LEDGFp75
Year | Milestone | References |
---|---|---|
1994 | Discovery of serum autoantibodies recognizing the nuclear DFS-IIF pattern in patients with interstitial cystitis | [4] |
1997 | Partial cDNA sequence encoding the autoepitope region of the DFS70 autoantigen deposited in GenBank under accession number U94319 | [3] |
1998 | Discovery of transcription co-activator p75, later known to be identical to DFS70 and LEDGFp75 | [13] |
1999 | Discovery of LEDGFp75 using autoantibodies from a cataract patient | [14] |
2000 | Characterization of DFS70 using autoantibodies from patients with atopic dermatitis and other conditions, and initial observation that these autoantibodies are present at low frequencies in SARD patients | [3] |
2001–2002 | Demonstration that DFS70/LEDGFp75 is cleaved during cell death into fragments that are recognized by autoantibodies | |
2003–2004 | Discovery of DFS70/LEDGFp75 as a key cellular co-factor of HIV-1 integration | |
2004 | Initial observation that anti-DFS70/LEDGFp75 autoantibodies are present in apparently healthy individuals | [125] |
2004 | Identification of a major B cell autoepitope in the carboxy-terminal region of DFS70/LEDGFp75 | [62] |
2005 | Identification of DFS70/LEDGFp75 as a tumor associated autoantigen | [99] |
2005 | Demonstration that anti-DFS70/LEDGFp75 autoantibodies are a very common occurrence in human sera screened for ANAs by HEp-2 IIF in a clinical laboratory and can be detected in a wide array of immunological conditions | [7] |
2008 | Observation that patients producing anti-DFS70/LEDGFp75 autoantibodies as the only serum ANA pattern are rarely diagnosed with SARD | [28] |
2011–2012 | Description of anti-DFS70/LEDGFp75 autoantibodies as a potential exclusion biomarker for SARD | |
2012 | Development of a highly specific ANA test based on immunoadsorption of anti-DFS70/LEDGFp75 autoantibodies | [5] |
2012 | Introduction of a new algorithm for ANA testing that considers anti-DFS70/LEDGFp75 autoantibodies | [6] |
2013 | First commercially available diagnostic test (Inova Diagnostics) for the detection of anti-DFS70/LEDGFp75 antibodies | N/A |
General properties of anti-DFS70/LEDGFp75 autoantibodies
DFS70/LEDGFp75 structure and function
Gene and spliced variants
Structural and functional domains
Autoepitope mapping in DFS70/LEDGFp75
Cellular and tissue expression of DFS70/LEDGFp75
Cellular functions of DFS70/LEDGFp75
Protection against environmental stress
Gene | Description | Method of discovery | Validation | References |
---|---|---|---|---|
ADH and | Alcohol dehydrogenase and | EMSA | Transcription reporter assays | [78] |
ALDH | aldehyde dehydrogenase | |||
ALB | Albumin | qPCR Array RNAi, overexpression | qPCR | [82] |
AOP2/PRDX6 | Antioxidant protein 2/Peroxiredoxin 6 | DNase I footprinting, EMSA | Transcription reporter assays, qPCR, immunoblotting | [74] |
CYGB | Cytoglobin | qPCR Array RNAi, overexpression | qPCR, immunoblotting | [82] |
HOX genes | Homeobox genes | Gene microarray, RNAi | qPCR | |
HSP27 | Heat shock protein 27 | DNase I footprinting | Transcription reporter assays, RT-PCR, RNAi | |
IL-6 | Interleukin 6 (interferon, beta 2) | qPCR, immunoblotting, overexpression | RNAi | |
INV | Involucrin | EMSA | Transcription reporter assays, qPCR, immunoblotting, IHC | [75] |
PIP3-E/IPCEF-1 | Phosphoinositide-binding protein/Interacting protein for cytohesin exchange factor 1 | RT-Profiler qPCR Array RNAi, overexpression | qPCR | [82] |
SOD3 | Superoxide dismutase 3 | qPCR Array, RNAi, overexpression | qPCR | [82] |
TPO | Thyroid peroxidase | qPCR Array, RNAi, overexpression | qPCR | [82] |
VEGF-C | Vascular endothelial growth factor C | ChIP | RT-PCR, immunoblotting, transcription reporter assays | |
αB crystallin | Small stress protein alpha basic crystallin | DNase I footprinting | Transcription reporter assays, RT-PCR, EMSA, RNAi | |
γ-GCS-HS | Gamma glutamyl cysteine synthetase-heavy subunit | Transcription reporter assays | qPCR, immunoblotting, RNAi | [71] |
DFS70/LEDGFp75 interactome
Cell death and survival decisions
Regulation of DFS70/LEDGFp75 expression and function
Transcriptional regulation
Functional regulation by repression of transcription function
Functional regulation by sumoylation
Crosstalk between DFS70/LEDGFp75 and inflammatory pathways
Clinical associations of anti-DFS70/LEDGFp75 autoantibodies
Category | Reactivity (positive/total) | Frequency (%) | Detection methods | References |
---|---|---|---|---|
Alopecia areata | 22/111 | 20 | HEp-2 IIF, WB, ELISA | [21] |
Arthralgia | 16 of 81 DFS-positive sera | 19.8 | HEp-2 IIF | [7] |
2 of 34 DFS-positive sera | 5 | HEp-2 IIF, CIA | [130] | |
Asthma | 8/50 | 16 | HEp-2 IIF, WB | [3] |
1/25 | 4 | CIA | [107] | |
Atopic dermatitis | 19/64 | 29.6 | HEp-2 IIF, WB, | [3] |
15/21 (children) | 71.4 | ELISA | [108] | |
23/61 | 37.7 | ELISA | [23] | |
0/16 | 0 | CIA | [107] | |
Atopic dermatitis with cataract | 8/8 | 100 | ELISA | [108] |
Atypical retinal degeneration | ND (3 case studies) | NA | WB, SEREX | [110] |
Autoimmune fatigue syndrome | 226 cases, reactivity not clearly stated | ~40 | ELISA, WB | [115] |
Autoimmune thyroiditis | 13 of 81 DFS-positive sera | 16 | HEp-2 IIF | [7] |
4/67 | 6 | CIA | [107] | |
Behcet’s disease | 11/32 | 34.4 | ELISA | [25] |
Blood bank donors | 35/650 | 5.4 | ELISA | [108] |
Cancer (various types) | 6/334 | 1.8 | HEp-2 IIF | [22] |
0/40 | 0 | HEp-2 IIF, CIA | [107] | |
3 of 81 DFS-positive sera | 3.7 | HEP-2 IIF | [7] | |
Clinical referrals or routine | 53/3263 | 1.6 | HEp-2 IIF, ELISA, CIA | [107] |
ANA testing | 5,081 of 13,641 ANA-positive sera | 37 | HEp-2 IIF | [7] |
172/21,516 | 0.8 | HEp-2 IIF | [22] | |
101/2,654 | 3.8 | HEp-2 IIF | [128] | |
101 of 352 ANA-positive sera | 28.7 | HEp-2 IIF | [128] | |
57/2,788 | 2 | HEp-2 IIF | [129] | |
57 of 790 ANA-positive sera | 7.2 | HEp-2 IIF | [129] | |
Chronic fatigue syndrome | 2/60 | 3.3 | HEp-2 IIF, WB | [3] |
2 of 81 DFS-positive sera | 2.5 | HEp-2 IIF | [7] | |
18 of 21 ANA-positive children | 86 | HEp-2 IIF, WB | [116] | |
36 cases, reactivity not clearly stated | ~40 | ELISA, WB | [115] | |
Diverse dermatological conditions | 39 of 115 ANA-positive sera | 34 | HEp-2 IIF | [128] |
Dermatomyositis/polymyositis | 4/80 | 5 | HEp-2 IIF, WB | [28] |
7/116 | 6 | HEp-2 IIF, ELISA | [123] | |
Diffuse pain | 21 of 81 DFS-positive sera | 26 | HEp-2 IIF | [7] |
Fibromyalgia | 3 of 81 DFS-positive sera | 3.7 | HEp-2 IIF | [7] |
3 of 34 DFS-positive sera | 9 | HEp-2 IIF, CIA | [130] | |
1 of 15 ANA-positive children | 4.8 | HEp-2 IIF, WB | [116] | |
Graves disease | 1/60 | 1.7 | CIA | [107] |
Gynecologic syndromes | 2 of 81 DFS-positive sera | 2.5 | HEp-2 IIF | [7] |
Healthy donors | 0/39 | 0 | HEp-2 IIF, WB | [3] |
8/37 | 21.6 | ELISA | [25] | |
64/597 | 11 | HEp-2 IIF, WB, ELISA | [125] | |
8/105 | 7.6 | WB, ELISA | [21] | |
11/124 | 8.9 | HEp-2 IIF, ELISA, | [107] | |
39/918 | 4.2 | CIA HEp-2 IIF | [26] | |
39 of 118 ANA-positive sera | 33.1 | HEp-2 IIF | [26] | |
16 of 34 DFS-positive sera | 47 | HEp-2 IIF, CIA | [130] | |
Infectious diseases | 0/20 | 0 | CIA | [107] |
6 of 81 DFS-positive sera | 7.4 | HEp-2 IIF | [7] | |
Inflammatory bowel disease | 0/34 | 0 | CIA | [107] |
Interstitial cystitis | 9/103 | 8.7 | HEp-2 IIF, WB | [3] |
2/40 | 5 | CIA | [107] | |
Multiple sclerosis | 0/10 | 0 | CIA | [107] |
1 of 81 DFS-positive sera | 1.2 | HEp-2 IIF | [7] | |
2 of 172 DFS-positive sera | 1.2 | HEp-2 IIF | [22] | |
Prostate cancer (PCa) | 46/206 | 22.3 | HEp-2 IIF, ELISA, WB | [99] |
Matched controls for PCa | 9/164 | 5.4 | ELISA | [99] |
Rheumatoid arthritis | 0/30 | 0 | HEp-2 IIF, WB, | [3] |
0/40 | 0 | HEp-2 IIF, WB, ELISA | [125] | |
16 of 172 DFS-positive sera | 9.3 | HEp-2 IIF | [22] | |
1/39 | 2.6 | CIA | [107] | |
2 of 81 DFS-positive sera | 2.4 | HEp-2 IIF | [7] | |
0/13 | 0 | HEp-2 IIF, WB | [28] | |
11/65 | 16.9 | HEp-2 IIF | [128] | |
2/13 | 15.3 | HEp-2 IIF | [128] | |
2 of 34 DFS-positive sera | 5.8 | HEp-2 IIF, CIA | [130] | |
Sarcoidosis | 4/16 | 25 | ELISA | [25] |
Scleroderma/systemic sclerosis | 1/40 | 2.5 | HEp-2 IIF, WB | [3] |
0/50 | 0 | HEp-2 IIF, WB, ELISA | [125] | |
2 of 172 DFS-positive sera | 1.2 | HEp-2 IIF | [22] | |
0/29 | 0 | CIA | [107] | |
1/164 | 0.006 | HEp-2 IIF, WB | [28] | |
1 of 91 DFS-positive sera | 1.1 | CIA | [24] | |
Sjögren’s syndrome | 2/29 | 6.9 | HEp-2 IIF, WB | [3] |
2/30 | 6.7 | HEp-2 IIF, WB, ELISA | [125] | |
4 of 172 DFS-positive sera | 2.3 | HEp-2 IIF | [22] | |
0/7 | 0 | CIA | [107] | |
8/71 | 11.3 | HEp-2 IIF, WB | [28] | |
2 of 34 DFS-positive sera | 5.8 | HEp-2 IIF, CIA | [130] | |
Systemic lupus erythematosus | 0/36 | 0 | HEp-2 IIF, WB | [3] |
1/55 | 2 | HEp-2 IIF, WB, ELISA | [125] | |
5 of 172 DFS-positive sera | 2.9 | HEp-2 IIF | [22] | |
7/251 | 2.8 | CIA | [107] | |
5 of 81 DFS-positive sera | 6.2 | HEp-2 IIF | [7] | |
7/124 | 5.6 | HEp-2 IIF, WB | [28] | |
4 of 91 DFS-positive sera | 4.3 | CIA | [24] | |
Sympathetic ophthalmia | 5/7 | 71.4 | ELISA | [25] |
Vogt–Koyanagi–Harada Syndrome | 24/36 | 66.7 | ELISA | [25] |